Literature DB >> 14561012

H. pylori and reflux esophagitis in Turkish patients living in the Zaanstreek region in the Netherlands.

R J L F Loffeld1.   

Abstract

There are data on the prevalence is of reflux esophagitis in a population with a high prevalence of H. pylori infection. A cross-sectional study was done in a Turkish population in The Netherlands. A total of 1640 consecutive patients with reflux esophagitis were included. Sixty-one patients were of Turkish descent. Reflux esophagitis occurred significantly more often in ethnically Dutchpeople (overall 33% vs. 9.7%, P < 0.001). H. pylori was present in 60.6% of Turkish patients and in 18.5% of Dutch patients. All Turkish patients only suffered from mild esophagitis. It is concluded that the occurrence of reflux esophagitis is low in a population of Turkish patients with a high prevalence of H. pylori.

Entities:  

Mesh:

Year:  2003        PMID: 14561012     DOI: 10.1023/a:1025428019317

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  11 in total

1.  Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis.

Authors:  J Labenz; A L Blum; E Bayerdörffer; A Meining; M Stolte; G Börsch
Journal:  Gastroenterology       Date:  1997-05       Impact factor: 22.682

2.  Opposing time trends of peptic ulcer and reflux disease.

Authors:  H B el-Serag; A Sonnenberg
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

Review 3.  Helicobacter pylori and gastro-oesophageal reflux disease: association and clinical implications. To treat or not to treat with anti-H. pylori therapy?

Authors:  R J L F Loffeld; R W M van der Hulst
Journal:  Scand J Gastroenterol Suppl       Date:  2002

4.  Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis.

Authors:  B F Werdmuller; R J Loffeld
Journal:  Dig Dis Sci       Date:  1997-01       Impact factor: 3.199

Review 5.  How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology.

Authors:  J Calam; A Gibbons; Z V Healey; P Bliss; N Arebi
Journal:  Gastroenterology       Date:  1997-12       Impact factor: 22.682

6.  Reflux esophagitis and hiatal hernia as concomitant abnormality in patients presenting with active duodenal or gastric ulcer: cross-sectional endoscopic study in consecutive patients.

Authors:  R J.L.F. Loffeld; A B.M.M. van der Putten
Journal:  Eur J Intern Med       Date:  2002-05       Impact factor: 4.487

7.  The occurrence of a duodenal or gastric ulcer in two different populations living in the same region: a cross-sectional endoscopical study in consecutive patients.

Authors:  R J Loffeld; A B van der Putten
Journal:  Neth J Med       Date:  2001-11       Impact factor: 1.422

Review 8.  A review of diagnostic techniques for Helicobacter pylori infection.

Authors:  R J Loffeld; E Stobberingh; J W Arends
Journal:  Dig Dis       Date:  1993       Impact factor: 2.404

9.  Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies.

Authors:  Loren Laine; Jennifer Sugg
Journal:  Am J Gastroenterol       Date:  2002-12       Impact factor: 10.864

10.  The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease.

Authors:  J J Vicari; R M Peek; G W Falk; J R Goldblum; K A Easley; J Schnell; G I Perez-Perez; S A Halter; T W Rice; M J Blaser; J E Richter
Journal:  Gastroenterology       Date:  1998-07       Impact factor: 22.682

View more
  2 in total

1.  Seroprevalence of Helicobacter pylori among children in Sana'a, Yemen.

Authors:  Hassan A Al-Shamahy
Journal:  Ann Saudi Med       Date:  2005 Jul-Aug       Impact factor: 1.526

2.  Vitamin B12 status in patients of Turkish and Dutch descent with depression: a comparative cross-sectional study.

Authors:  Yener Güzelcan; Peter van Loon
Journal:  Ann Gen Psychiatry       Date:  2009-08-13       Impact factor: 3.455

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.